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stability of radiomics features in 
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Bernard E. Van Beers4, Arend Heerschap5, Alan Jackson  6, Joachim E. Wildberger2, 
Felix M. Mottaghy2,7, Nandita M. Desouza3 & philippe Lambin1,2
Quantitative radiomics features, extracted from medical images, characterize tumour-phenotypes 
and have been shown to provide prognostic value in predicting clinical outcomes. Stability of radiomics 
features extracted from apparent diffusion coefficient (ADC)-maps is essential for reliable correlation 
with the underlying pathology and its clinical applications. Within a multicentre, multi-vendor trial 
we established a method to analyse radiomics features from ADC-maps of ovarian (n = 12), lung 
(n = 19), and colorectal liver metastasis (n = 30) cancer patients who underwent repeated (<7 days) 
diffusion-weighted imaging at 1.5 T and 3 T. From these ADC-maps, 1322 features describing tumour 
shape, texture and intensity were retrospectively extracted and stable features were selected using 
the concordance correlation coefficient (CCC > 0.85). Although some features were tissue- and/or 
respiratory motion-specific, 122 features were stable for all tumour-entities. A large proportion of 
features were stable across different vendors and field strengths. By extracting stable phenotypic 
features, fitting-dimensionality is reduced and reliable prognostic models can be created, paving the 
way for clinical implementation of ADC-based radiomics.
Diffusion-weighted magnetic resonance imaging (DWI) is widely used in oncology for identification and charac-
terization of tumours1, as well as localization2. Signal attenuation in DWI arises from Brownian motion of water 
molecules and reflects their interaction with cellular barriers and tissue macromolecules that restrict their mobil-
ity. DWI is used for tumour characterization and as an indirect biomarker of tissue cellularity3. By incorporating 
a number of diffusion-sensitizing gradients with varying strength, duration and time interval (i.e., b-values) into 
the MR pulse sequence, parametric apparent diffusion coefficients (ADC) maps can be derived. In oncology, 
ADC maps are used to determine tumour malignancy and assess early treatment response by quantifying the 
diffusion-related attenuation of MR signal intensity3,4. There is no consensus regarding the threshold value below 
which ADC is indicative of tumour, however ADC values around 1000 × 10−6 mm2/s are considered normal, 
while lower values generally reflect restricted diffusion that could relate to hyper-cellularity or hyper-viscosity 
characteristic of tumour tissue, and higher ADC values represent fluid filled regions where water diffusion is 
unrestricted (e.g., cystic lesions, necrotic tissue). Unfortunately, an overlap between ADC values characteristic 
of active and treated tumours often reduces the utility of ADC in clinical decision-making and variations in esti-
mates of ADC resulting from lack of standardized DWI protocols do not allow the integration of absolute values 
of ADC as an objective, quantifiable biomarker for personalised healthcare in the clinic5–7.
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Radiomics may provide complementary information from ADC maps by high-throughput extraction of 
quantitative tumour phenotypic features (i.e., shape, texture, signal intensity, and wavelet features) that have pre-
viously been correlated with tissue pathology and treatment response prediction8,9. Please view https://youtu.
be/Tq980GEVP0Y for more information. This methodology has shown promising results for CT imaging in 
oncology and in the development of prediction modelling for treatment response and outcome10,11. For DWI, the 
variability of ADC across different MR systems, vendors and magnetic field-strengths potentially compromises 
the stability of radiomics features, limiting the clinical implementation of MR radiomics. In addition, there is a 
realistic risk of overfitting when building a model where the numbers of features extracted greatly outnumber the 
size of the study cohort. The majority of published radiomics analyses remove features due to redundancy, either 
because features correlate highly with each other, or because they do not correlate with the endpoint being ana-
lysed. Reducing the number of unstable features substantially increases the reliability of radiomics analyses and 
may not only improve correlation with underlying pathology and tumour biology, but may also allow construc-
tion of improved prognostic or predictive models12–14. Elimination of features with poor clinical reproducibility 
is critical for achieving a high radiomics quality score15.
The purpose of this analysis was to evaluate the stability of radiomics features extracted from ADC maps, 
derived from standardized test-retest DWI acquisitions embedded in prospective multicentre trials. DWI for each 
subject were acquired twice within 7 days, under similar conditions. We hypothesized that selected ADC-based 
features are generalizable and unaffected by different sources of data variability (i.e., tumour type, MR system, 
magnetic field strength) when applying standardized protocols on quality-assured MR scanners across multiple 
clinical centres. Establishing this methodology and presenting the results derived from the underpinning study 
would not only stimulate the clinical implementation of MR radiomics using ADC as a biomarker for tumour 
phenotyping16 but would also outline a generalizable method for other quantifiable MRI parameters.
Results
Feature stability. Based on previous work, we selected a threshold of 0.85 for the concordance correlation 
coefficient (CCC), whereby features above this threshold were considered stable between test and retest scans17. 
Figures 1 and 2 show an overview of the stability of test-retest radiomics features for all patient cohorts.
Tumour-type differences at 1.5 T. In 20 ovarian cancer lesions from 12 patients, 29% of all features (378/1322) 
were stable in test-retest ADC maps (Table 1). Of the unfiltered features, most stable features were related to 
geometric shape (22/24, 92%) and texture (37/99, 37%). A comprehensive list of all features is presented as sup-
plementary information. After wavelet decomposition, 144 additional radiomics features were calculated for all 
8 wavelet-filters, resulting in 27% (312/1152) of filtered features being stable. In 17 colorectal liver metastases 
from 17 patients, 25% of all extracted radiomics features (330/1322) demonstrated CCC-values greater than 0.85 
in 1.5 T ADC-maps. Of these stable features, 36% (61/170) of unfiltered and 23% (269/1152) of wavelet-filtered 
features were stable in colorectal liver metastases. For 22 lung cancer lesions from 19 patients, 25% of all features 
(330/1322) showed stability matching our specified threshold. In contrast to colorectal liver metastases, only 16% 
(27/170) of unfiltered radiomics signatures were stable, while the percentage of stable wavelet-filtered features 
were 26% (303/1152).
122 features (23 unfiltered and 99 wavelet-filtered) were regarded as stable in all three tumour entities and 
298 features (49 unfiltered and 249 wavelet-filtered) were stable for at least 2 tumour-types on 1.5 T ADC maps 
(Fig. 3A, Supplementary Fig. S1). Statistically significant differences in CCC from all features (unfiltered and 
wavelet-filtered) were found between ovarian tumours and colorectal liver metastases (P < 0.0001), and between 
colorectal liver metastases and lung cancer (P = 0.0051) but not between ovarian and lung cancer (P = 0.56).
Magnetic field strength differences. The effects of magnetic field strength differences were analysed in ADC-maps 
acquired at 1.5 T and at 3 T in 17 and 13 patients with colorectal liver metastases, respectively. On ADC maps 
acquired at 3 T, 32% (425/1322) of radiomics features were stable over 13 segmented lesions from test-retest scans 
(Table 2). These consisted of 71/170 unfiltered features (i.e., 13/24 (54%) geometric shape features, 44/99 (44%) 
texture features, and 14/47 (30%) intensity features) and 355/1152 (29%) of wavelet-filtered features.
No statistically significant differences were found in stability between features extracted from ADC maps 
acquired at 1.5 T and 3 T (P = 0.51). Correspondingly, 245 extracted features (42 unfiltered and 204 filtered) were 
shown to be stable in both populations, regardless of magnetic field strength (Fig. 3B, Supplementary Fig. S2). 
Furthermore, comparable mean and median ADC values were derived from both 1.5 T- and 3 T-ADC maps of 
the entire cohort (Table 2).
Cross-vendor differences. Vendor-specific subgroups were analysed within the dataset of colorectal liver metas-
tases acquired at 3 T (site F). As shown in Table 3, feature stability of ADC maps acquired on a Philips Ingenia 
and a GE Discovery MR-system presented CCC-values > 0.85 for 521/1322 (39%) and 506/1322 (38%) fea-
tures, respectively. No statistically significant differences were found in the number of features that exceeded the 
CCC-threshold (P = 0.49). However, 290 features (79 unfiltered and 211 filtered) presented high stability across 
both vendors’ test-retest data (Fig. 3C, Supplementary Fig. S3). Furthermore, 154 features (34 unfiltered, 120 
filtered) were stable in both cross-vendor and in both 1.5 T and 3 T datasets.
A detailed description of stable features is described in Supplementary Tables S1-S4 for each subgroup and 
listed as supplementary information (online-only).
Correlations between features and tumour volume. Across all tissue types and centres, the mean 
absolute of Spearman’s r (|r|) was 0.34 ± 0.23. The distribution of Spearman’s r values for all features can be seen 
in Supplementary Fig. 4. A total of 73 features were found to correlate highly with tumour volume (|r| > 0.8), 10 
3Scientific RepoRts |          (2019) 9:4800  | https://doi.org/10.1038/s41598-019-41344-5
www.nature.com/scientificreportswww.nature.com/scientificreports/
of which were shape features such as maximum diameter and surface, and the remaining 63 were made up of 7 
texture features and their 56 wavelet filtered equivalents. A further 137 features correlate strongly (|r| > 0.6) with 
volume, of which 11 are texture features, two intensity histogram features, and one is a statistical feature, their 
associated 112 wavelet features, an additional shape feature, and 10 further wavelets of texture features. For all 
unfiltered features, Supplementary Fig. 5 shows the correlation between |r| and CCC for all tumour sites while 
Supplementary Fig. 6 details the strength of the correlations with tumour volume.
Figure 1. Stability of test-retest radiomics features for all lung and ovarian. cancers The threshold for stability 
was set at concordance correlation coefficients (CCC) greater than 0.85.
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Discussion
Within a multicentre trial, we present a method of data analysis to evaluate the stability of radiomics features 
derived from parametric MRI. This approach has shown that a substantial fraction of ADC-based radiomics 
features (25–29%) presented test-retest stability over a variety of tissues, MR-systems, and vendors. In addition, 
122 features were stable over all tissues and could be regarded to be independent of tumour origin. These results 
regarding radiomics feature stability are in line with studies that analysed repeatability of absolute ADC values, a 
correlation that could be attributed to the low coefficient of variance (CoV) presented in these studies5,18,19. The 
methodology for stable feature selection and volume correlation presented in this analysis, together with the list 
Figure 2. Stability of test-retest radiomics features for all collorectal liver metastases acquired at 1.5 T and 3 T. 
The threshold for stability was set at concordance correlation coefficients (CCC) greater than 0.85.
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of repeatable ADC radiomics features, facilitate the development of reliable MR-based radiomics signatures, and 
future clinical implementation across multiple centres. We therefore postulate that this method of analysis can be 
generalized to a larger field of quantifiable MR imaging features.
Shape features describe the volume contained within the segmentation, rendering it volume-dependent. 
Mismatch in shape features between test and retest scans could thus be attributed to differences in tumour seg-
mentation and inter-observer variability although the same observer outlined the test-retest data in this study20. 
Especially in lung cancer, accurate tumour segmentation is complicated by respiratory motion and motion-related 
MR artefacts which vary between test-retest studies. Since DWI protocols in the lung were acquired during 
free-breathing, low stability of shape features is expected. However, these results were also present in radiomics 
analyses of CT-images where the acquisition is done in breath-hold17. Tumorous lesions in the liver and ovaries 
are less subjected to respiratory motion and as expected produced shape features with higher stability.
Tumour type 
(1.5 T)
ADC Mean ± SD 
(10−6 mm2/s)
Stable features (CCC > 0.85)
Unfiltered Wavelet 
filtered
ALL 
(unfiltered + wavelet)Intensity Shape Texture
Ovarian 1086.2 ± 191.9 7/47 22/24 37/99 312/1152 378/1322 (29%)
Colorectal Liver 979.2 ± 420.9 8/47 20/24 33/99 269/1152 330/1322 (25%)
Lung 1340.2 ± 412.5 1/47 13/24 13/99 303/1152 330/1322 (25%)
Table 1. Stable features in ADC maps acquired at 1.5 T over different tumour-entities (i.e., 20 ovarian cancer 
lesions, 17 colorectal liver metastases, 22 lung cancer lesions).
Figure 3. Overlapping results in feature stablility extracted from 1.5 T-MR images of (A) all tumour-entities 
(i.e., colorectal liver metastases (red), ovarian cancer (yellow), and lung cancer (blue)); derived from MR images 
of colorectal liver metastases (B) acquired at 1.5 T (red) and 3 T (yellow); and obtained from 3 T-MR images of 
colorectal liver metastases (C) acquired on a Philips Ingenia (red) and GE Discovery (yellow).
Magnetic field 
(Colorectal Liver)
ADC Mean ± SD 
(10−6 mm2/s)
ADC Median 
(10−6 mm2/s)
Stable features (CCC > 0.85)
Unfiltered
Wavelet 
filtered
ALL 
(unfiltered + wavelet)
1.5 T 979.2 ± 420.9 953.4 61/170 269/1152 330/1322 (25%)
3 T 1353.3 ± 409.8 1202.6 71/170 355/1152 425/1322 (32%)
Table 2. Test-retest feature stability of colorectal liver metastases measured on 1.5 T (n = 17) and 3 T ADC 
maps (n = 13).
Site F  
(Colorectal Liver, 3 T)
ADC Mean ± SD 
(10−6 mm2/s)
ADC Median 
(10−6 mm2/s)
Stable features (CCC > 0.85)
Unfiltered
Wavelet 
filtered
ALL 
(unfiltered + wavelet)
Philips 1237.9 ± 324.4 1129.8 106/170 415/1152 521/1322 (39%)
GE 1752.3 ± 395.6 1882.9 100/170 406/1152 506/1322 (38%)
Table 3. Test-retest feature stability of colorectal liver metastases measured on 3 T ADC maps acquired on a 
Philips Ingenia (n = 10) and GE Discovery (n = 8) MR systems at the same clinical centre.
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Texture features describe the pattern distribution of the voxels and quantify intra-tumour heterogeneity in all 
three dimensions21. As it takes into consideration the spatial relation to nearby voxels, stability across test-retest 
were similar to those of the shape features. In lung cancer, MR-related susceptibility artefacts are more com-
mon in DWI with distortions at the boundaries of tumour and air-filled lung tissue11. Hard transitions between 
tumours and normal lung tissue further complicate tumour segmentation as small delineation differences could 
have large impact on ADC measurements20. Nevertheless, radiomics features derived from lung cancer ADC 
maps achieved comparable reproducibility after wavelet-filtering, which can alleviate boundary inhomogeneity, 
justifying the use of ADC-based radiomics in multi-centre trials in lung cancer.
Intensity features in lung cancer also showed more variance compared to colorectal liver metastases and 
ovarian cancer. As the DWI protocol in lung cancer was acquired in free-breathing, variation in partial vol-
ume effects during test-retest are very likely to have been responsible for the high variation of the intensity fea-
tures. There are several other reasons for variability in intensity feature stability in MRI. Unlike CT, variations 
in signal-intensity result from differences in RF coil sensitivity and coil placement during patient repositioning. 
Despite attempting to mitigate this by using ADC rather than absolute values of signal-intensity on high b-value 
images, intensity-features generally showed low stability. Although no treatment was administered to our patients 
between test-retest scans, eliminating the possibility of treatment-related physiological effects3,22, inflammatory 
processes associated with the tumour (e.g., lung-cancer atelectasis) and small molecular fluctuations of thermal 
diffusion, may also have affected the stability of the ADC intensity features23.
Stability of radiomics features was unaffected by differences in magnetic field strength, matching the 
field-independent nature of ADC3. In the literature, no significant difference has been reported between 1.5 T 
and 3 T ADC values measured in multiple organs24,25. However, higher mean CoVs have been reported in 3 T 
abdominal ADC24. Potentially, this variability is associated with increased difficulty in maintaining homogenous 
excitation pulses and gradient linearity at higher magnetic fields, and to the presence of artefacts related to mag-
netic susceptibility and eddy currents25.
Surprisingly, no statistically significant differences in feature stability were found between vendors, despite 
potential technical differences (e.g., imaging algorithms, shimming, fat suppression, and ADC reconstruction) 
(P = 0.49)23,26. Previously, studies have shown low longitudinal inter-vendor ADC variability when evaluat-
ing an ice/water phantom (CoV = 1–4%) and cancer patients (CoV ≤ 10%)16,27,28. High repeatability and low 
inter-scanner variation of ADC measurements could have a direct positive effect on radiomics feature stability.
Radiomics features derived from CT-images have been shown to have a prognostic value9. For CT, these 
included tumour intensity (‘energy’), texture (‘Grey-level non-uniformity’), wavelet (Grey-level non-uniformity 
HLH’) and shape (‘compactness’). These features were also highly stable in all tumour types in our data with 
CCC-values ranging from 0.89–0.99 (Fig. 1). This opens the possibility that similar radiomics features derived 
from ADC data might be useful in model-building, or in complementing the currently used method of detecting 
treatment-related changes by analysing absolute ADC metrics (i.e., histogram analysis of centiles, kurtosis and 
skewness)18.
Radiomics studies in CT and positron emission tomography have suggested that some reproducible features 
could be a surrogate of tumour volume29,30. This appears to hold true for some but certainly not the majority of 
the stable features presented in this research, and knowledge of which features correlate highly with volume is 
important for any radiomics study moving forward. Since radiomics should be purely quantitative imaging, no 
prognostic or diagnostic features should be excluded a priori, including simple ones such as volume or those that 
correlate with it.
Our analysis methods and underpinning study set-up had some limitations. Although efforts were made to 
minimise sources of variability by using a quality-assured standardized protocol and excluding b-values below 
100 mm/s2 from ADC reconstruction to reduce perfusion-related MR-signal, the use of a standardised protocol 
within a multi-site study does not permit optimization of data from individual MR-systems26. Furthermore, DWI 
protocols did not include respiratory triggering or motion correction. Motion artefacts, predominantly seen in 
lung cancer patients and patients with colorectal liver metastases (site C, 3 T), had an adverse effect on ADC fea-
ture stability. However, for the colorectal liver metastases data acquired at 3 T, the protocol was adjusted from the 
one specified at 1.5 T to avoid specific image-artefacts24. For example, a larger bandwidth of 1500–2650 Hz/pixel 
was set to minimise geometric image distortion. In addition to standardised DWI acquisition, we did not specif-
ically reduce ADC variability through post-processing to further improve the stability of radiomics features31. In 
a recent multi-centre study by Pathak et al., the percentage change in test-retest ADC measurements decreased 
from 21.1% to 2.7% in colorectal liver metastases using a standardization-strategy to account for measurement 
uncertainty (i.e., error modelling). This type of approach has the potential to further improve the stability of 
radiomics features. In addition, radiomics stability could benefit from improvements in tumour segmentation 
(i.e., reducing inter- and intra-observer variability) and image quality (i.e., increased signal-to-noise ratio and 
reduced image artefacts)5,6,20,31. Although we controlled for observer segmentation (same observer segmented 
each test-retest), image reconstruction and processing algorithms varied between centres and scanner vendors. 
Neither the assessment of differences between medical centres nor the number of reproducible features as a func-
tion of CCC cut-off (as performed in17) were included in this study owing to the small number of patients from 
each site and should be addressed in future work. However, good agreement in ADC-measurements between 
centres previously has been reported27. Also, image pre-processing can be regarded as another variable in the 
feature extraction workflow, and as such is also able to influence feature variability, so minimal pre-processing 
was performed, using common values from radiomics literature. Performing test-retest experiments are cru-
cial in order to ensure that only stable features are selected for meaningful analysis and inclusion of parametric 
MR-radiomics as a clinical tool15.
In conclusion, we have presented the assessment of stability of radiomics features from parametric ADC 
based on standardized test-retest measurements. This methodology enables selection of stable features that 
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quantitatively represent phenotypic features and enables the exciting use of high-quality radiomics analysis to 
attain reliable biomarkers complementary to other clinical/imaging data. As extracted ADC-based radiomics 
features are stable across multiple centres, tumour types, 1.5 T-3 T systems, and MR-vendors, this analysis can be 
widely included in multicentre trials. The implementation of such quantitative analysis of tumour phenotype will 
facilitate the development of diagnostic and theragnostic models that could help detect cancers earlier than the 
current standard, predict early treatment response and improve treatment decision-making towards personalized 
healthcare.
Methods
Patient population. As part of prospective clinical trials to qualify ADC imaging biomarkers and stability 
performed by the Quantitative Imaging in Cancer: Connecting Cellular Processes with Therapy (QuICConCePT) 
consortium (lung and liver) and the Cancer Research UK (ovary), sixty-one patients were included from 6 uni-
versity hospitals across the UK, Italy, France, and the Netherlands (site A-C, and E-G). Included patients were 
diagnosed with either lung cancer stage III18, ovarian cancer (Winfield et al., personal communication), or 
colorectal liver metastases32, and had a minimum of two imaging sessions maximally 7 days apart before start 
of treatment. Patient cohorts are summarized in Table 4. This study was approved by the institutional medical 
ethics committee of each centre (Medical Ethical Committee VU University Medical Centre, Ethics Committee 
Humanitas Milan, INSERM Ethics Committee, University Research Ethics Committee at the University of 
Manchester, Commissie Mensgebonden Onderzoek regio Arnhem – Nijmegen (WMO) at the Radboud University 
Medical Centre Nijmegen, and the Research Ethics Committee for The Royal Marsden Hospital Sutton). Formal 
written informed consent was recorded for each participant and all data analyses were compliant to the Medical 
Research Involving Human Subjects Act (WMO).
Image acquisition. Patients were scanned twice within 7 days before the start of treatment. In total, DWIs 
were acquired on 4 different MRI systems of 1.5 Tesla (T) and 3 different MRI systems of 3 T using a common 
scan protocol per tumour region (Table 5): on 1.5 T - GE Signa HDxt (site A), Philips Achieva DS (site B,G) 
Siemens Magnetom Avanto (site C,E), and on 3 T Siemens Magnetom Trio Tim (site C), Philips Ingenia (site 
F), and GE Discovery 750 w (site F). The applied MR-protocol was comprised of T1/T2-weighted images for 
anatomical imaging and diffusion-weighted sequences with three b-values. For DWI of each tumour-type, a 
common and quality-assured protocol was applied by all centres27 (Table 5). ADC maps were constructed by 
mono-exponential linear fitting of diffusion data. Images with b-values smaller than 100 s/mm2 were excluded to 
minimize components of blood perfusion in parametric ADC maps.
Segmentation. Volumes-of-interest (VOI) were manually delineated over all primary tumours and metas-
tases on DWI images with high b-value. The gross tumour volume (GTV) was determined at central review 
by experienced radiologists (with a minimum of 2 years experience) using all diagnostic information available, 
and saved as binary masks. For each patient, the same observer segmented the same lesion in both test-retest 
images, while at the same time making sure that no large anatomical variations occurred. After voxel-wise rigid 
Tumour site Tumour type Number Age range Treatment received
Lung NSCLC/metastases 19 41–86 5 naïve, 14 previously treated
Liver Colorectal metastases 30 44–77 No treatment within 6 months
Ovary High grade serous 12 31–77 Naïve
Table 4. Main patient cohort characteristics.
Lung Cancer 
(site A, B, E, G)
Colorectal liver metastases 
(1.5 T) (site A, B, C, E)
Colorectal liver metastases 
(3 T) (site C, F*)
Ovarian cancer 
(site E)
Sequence ss-EPI ss-EPI ss-EPI ss-EPI
TR (ms) ≥8000 ≥8000 5000 ≥8000
TE (ms) minimum minimum minimum minimum
NSA 4 4 2–4 4
FOV (mm2) 380 × 273 380 × 380 380 × 273 332 × 380
Matrix 128 × 112 128 × 128 128 × 128 128 × 112
Bandwidth (Hz/px) 1400–1800 1400–1800 1500–2650 1400–1800
Slice thickness (mm) 5 5 5–6 6
Slice gap (mm) 0 0 0 0
Pixel size (mm2) 3 × 3 1.5 × 1.5 1.5 × 1.5 1.5 × 1.5
b-values 100, 500, 800 100, 500, 900 150, 400, 800 100, 500, 900
Fat saturation yes yes yes yes
Parallel imaging yes yes yes yes
Table 5. Diffusion-weighted MR scan protocol. (*) Philips Ingenia and GE Discovery.
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registration, tumour delineations on DWI were transferred to corresponding ADC maps. If ≥2 tumours were 
present, the 2 largest lesions were delineated while excluding cystic or necrotic regions from segmentations. 
The same lesion was delineated separately on retest-data while blinded from test-data. In total, 72 lesions were 
included for analysis. All segmentations were performed using OsiriX (Pixmeo SARL, Bernex, SUI), Mirada RX 
(Mirada Medical, Oxford, UK), or Adept (in-house software, Institute of Cancer Research, London, UK).
Feature extraction. Radiomics features were retrospectively extracted from each VOI in the test-retest 
ADC dataset. ADC maps were pre-processed in two steps: (1) in order to reduce image noise and grey-level 
matrix (GLM) size, images were rescaled using a bin-size of 25 grey levels; (2) in order to standardise voxel size 
across all datasets, images were rescaled using a linearly resampled into isotropic voxel-sizes of 3 × 3 × 3 mm3,33. 
A total of 1322 radiomics features were obtained using an in-house developed software-toolbox in MATLAB 
2014a (Mathworks, Natick, USA)21. These features included signal intensity features (n = 47), geometric fea-
tures (n = 24), and texture features (n = 99), which respectively described the histogram-distribution of voxel 
intensity-values (i.e, first-order grey-level statistics, local intensity (Locint), and intensity histogram (IH) fea-
tures), the 3D shape of delineated volumes, and the spatial distribution of fractal dimensions and voxel intensities 
using 6 texture matrices (i.e., grey-level co-occurrence (GLCM, 26 features)34, grey-level distance-zone (GLDZM, 
16 features)35, grey-level run-length (GLRLM, 16 features)5,36, grey-level size-zone (GLSZM, 16 features)37, 
neighbouring grey-level dependence (NGLDM, 17 features)38, and neighbourhood grey-tone difference matrix 
(NGTDM, 5 features)39. Furthermore, 3D wavelet decompositions of the original image resulted in additional 
1152 features focusing on different spatial frequency ranges within tumour values9.
A mathematical description of all features was previously published in9,21,40 and were presented as supplemen-
tal material with permission of the corresponding authors. Most features used in this study are in compliance with 
feature definitions as described by the Imaging Biomarker Standardization Initiative (IBSI). Where features differ, 
a note has been added specifying the difference.
Statistical analysis. To select stable radiomics features, the pairwise concordance correlation coefficient 
(CCC) was calculated between data derived from the test and retest ADC images41. CCC-values range from −1 
to +1 and describe the negative or positive agreement between 2 datasets. Based on previous work, features with 
a minimum CCC of 0.85 were regarded as statistically stable and robust17,40,42. Stability is defined as the closeness 
of agreement between measured quantity values obtained by replicate measurements performed under the same 
conditions (e.g., patient, scanner, imaging protocol)18. Statistical differences in stable features between tumour 
types, and between MR-systems with different magnetic field strengths were tested using Kruskal-Wallis 1-way 
ANOVA with Dunn’s correction for multiple testing. Differences between MR-systems from different vendors 
were tested for statistical significance using a Mann-Whitney test. All statistical analyses were performed using 
GraphPad Prism version 6.01 (GraphPad, USA). P-values < 0.05 were considered statistically significant.
Feature correlation with tumour volume. Features with a constant value (or near-zero variance) across 
all images in the test dataset were excluded, and the remainder were examined for correlations with the tumour 
volume using Spearman’s rho statistic to estimate a rank-based measure of association. The Spearman coefficients 
of all unfiltered features were plotted against the feature stability as measured by the CCC for all tumour types 
and field strengths.
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